RecruitingPhase 3NCT06351501

Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering From Gender Dysphoria


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

60 participants

Start Date

Jun 25, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Gender dysphoria (GD) is a significant suffering lasting more than 6 months in a subject, with regard to the discrepancy felt between his or her gender identity and his or her birth sex. From the onset of puberty, most of these self-identified transgender adolescents will persist in their transgender identity and will undergo hormonal and surgical reassignment when the time comes. International best practice guidelines recommend early treatment from the start of pubertal development to block pubertal progression, with the possibility of hormonal transition by administering sex hormones of the desired sex usually around the age of 15.5. However, in order to reduce the psychosocial consequences of GD, more and more referral teams are carrying out this transition from the age of 13.5, although no study has been published to show its benefit compared with a transition at the age of 15.5. In the absence of treatment, co-morbidity among adolescents suffering from gender dysphoria is very high, with anxiety-depressive states, suicidal risk and dropping out of school in the forefront. Our hypothesis is that hormonal transition started at an age closer to physiological puberty can significantly reduce this comorbidity and improve quality of life for these adolescents. This is the first therapeutic trial to be conducted in France in the transgender adolescent population, in an area where international recommendations based on the principles of Evidence Based Medicine are essentially derived from the clinical expertise of teams who have specialized in the care of transgender people for over forty years, while clinical data derived from structured research are still very scarce. The results of this study will guide the care of transgender adolescents, allowing them, if the study is positive, to access hormonal treatments earlier and thus more quickly improve their overall functioning, anxiety-depressive symptoms and their quality of life.


Eligibility

Min Age: 156 MonthsMax Age: 168 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months and a drug called hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months for people with gender dysphoria. The study is currently recruiting participants at 4 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGhormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months

4 years of follow up (FU) with evaluation at T0 (13.5 years old +/- 6 months), T1 (15.5 years old +/-6 months) and T2 (17.5 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)

DRUGCross sex hormones ( œstrogenes or testosterone) started at 15.5 years old +/- 6 months

2 years of hormonal treatment from 15.5 old +/- 6 months to 17.5 years old +/- 6 months


Locations(4)

Service de psychiatrie de l'enfant et de l'adolescent, GH Pitié-Salpêtrière

Paris, France

Service d'Endocrinologie et Diabétologie Pédiatrique, CHU Robert Debré

Paris, France

Service de Psychiatrie de l'enfant et de l'adolescent, CHU Robert Debré

Paris, France

Service Endocrinologie et Diabète de l'enfant, CHU Le Kremlin Bicêtre

Le Kremlin-Bicêtre, Île-de-France Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06351501


Related Trials